2026-06-14T03:31:54Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/201492024-11-28T17:36:05Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16967col_20.500.12105_16972

00925njm 22002777a 4500 dc Diaz-Beya, Marina author Brunet, S author Nomdedeu, J author Cordeiro, Anna author Tormo, M author Escoda, Lourdes author Ribera, J. M author Arnan, M author Heras, Inmaculada author Gallardo, David author Bargay Lleonart, Joan author Queipo de Llano, Maria Paz author Salamero, O author Marti, J. M author Sampol Mayol, Antonia author Pedro, C author Hoyos, M author Pratcorona, M author Castellano, JJ author Nomdedeu, M author Risueno, RM author Sierra, J author Monzo, M author Navarro, A author Esteve, Jordi author 2015-10 Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (>= 60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P = 0.0025), shorter leukemia-free survival (P = 0.026) and higher cumulative incidence of relapse (P = 0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P = 0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML. Diaz-Beya M, Brunet S, Nomdedeu J, Cordeiro A, Tormo M, Escoda L, et al. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. Blood Cancer J. 2015 Oct;5:e352. 10.1038/bcj.2015.76 2044-5385 Blood Cancer Journal http://hdl.handle.net/20.500.13003/10668 26430723 L606212831 2-s2.0-84943169416 http://hdl.handle.net/20.500.12105/20149 368920300002 The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia